Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.55 |
| ▸ | PPARG | P37231 | 13/20 | 0.51 |
| ▸ | PPARA | Q07869 | 9/20 | 0.51 |
| ▸ | PPARD | Q03181 | 9/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096712 | 0.97 | PPARG (0.53) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096908 | 0.92 | PPARG (0.58) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096840 | 0.92 | ACLY (0.51) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096655 | 0.91 | PPARG (0.57) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096700 | 0.88 | ACLY (0.52) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096688 | 0.88 | PPARG (0.55) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096833 | 0.87 | ACLY (0.51) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096595 | 0.87 | PPARG (0.65) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096917 | 0.86 | PPARG (0.53) | ACLYPPARGPPARAPPARD | |
| SCHEMBL12096941 | 0.85 | PPARG (0.52) | ACLYPPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | ACLY 3538/4885PPARG 423/4885PPARA 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.